Intra-Cellular Therapies Inc.
ITCI
ITCI was delisted on the 1st of April, 2025.
127 hedge funds and large institutions have $418M invested in Intra-Cellular Therapies Inc. in 2018 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 42 increasing their positions, 46 reducing their positions, and 18 closing their positions.
319% more call options, than puts
Call options by funds: $49.3M | Put options by funds: $11.8M
9% less repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 46
3% less funds holding
Funds holding: 131 → 127 (-4)
17% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 18
49% less capital invested
Capital invested by funds: $827M → $418M (-$409M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SC
Samlyn Capital
New York
|
+$7.99M |
| 2 |
Millennium Management
New York
|
+$6.16M |
| 3 |
GAI
General American Investors
New York
|
+$4.84M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$4.36M |
| 5 |
Two Sigma Investments
New York
|
+$3.11M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Balyasny Asset Management
Chicago,
Illinois
|
-$11M |
| 2 |
DFO
Duquesne Family Office
New York
|
-$6.45M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$6.01M |
| 4 |
CCP
Clough Capital Partners
Boston,
Massachusetts
|
-$5.93M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$5.39M |
ITCI Hedge Fund Activity: Q4 2018 in Review
127 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Intra-Cellular Therapies Inc. (ITCI) for Q4 2018, worth a combined $418M — down 49% from $827M a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of ITCI and 15 opened new positions — a net loss of 3 holders — while 46 trimmed existing stakes and 42 added.
The largest buyer was Samlyn Capital, adding an estimated $7.99M. The largest seller was Balyasny Asset Management, exiting entirely with an estimated $11M sold.
- 127 institutional investors held Intra-Cellular Therapies Inc. (ITCI) as of Q4 2018, down from 131 in Q3 2018.
- Funds reported $418M of Intra-Cellular Therapies Inc. stock for Q4 2018, down 49% quarter-over-quarter.
- 15 funds opened new Intra-Cellular Therapies Inc. positions in Q4 2018 and 18 closed out, a net change of -3 holders.
- The largest Intra-Cellular Therapies Inc. buyer in Q4 2018 was Samlyn Capital, an estimated $7.99M added.
- The largest Intra-Cellular Therapies Inc. seller in Q4 2018 was Balyasny Asset Management, an estimated $11M sold.
Based on aggregated 13F filings for Q4 2018.